Beta LT: Phase I/II

In an ongoing 14-28 patient Canadian Phase I/II trial, no adverse events or side effects have been seen in 3 bone marrow transplant patients enrolled to date who received the full target dose of Beta LT. The trial will assess immune parameters and tumor size. ...